Primus Remedies Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 29-07-2024
- Paid Up Capital ₹ 0.10 M
as on 29-07-2024
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.19 Cr
as on 29-07-2024
- Satisfied Charges ₹ 3.53 M
as on 29-07-2024
- Revenue 20.96%
(FY 2023)
- Profit 2.18%
(FY 2023)
- Ebitda 7.15%
(FY 2023)
- Net Worth 32.30%
(FY 2023)
- Total Assets 11.49%
(FY 2023)
About Primus Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹11.19 Cr. The company has closed loans amounting to ₹3.53 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Narayanam, Swapna Pasupunuri, Sridevi Jonnalagadda, and Five other members serve as directors at the Company.
- CIN/LLPIN
U24232MH2010PTC200506
- Company No.
200506
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Dombivili, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Primus Remedies Private Limited offer?
Primus Remedies Private Limited offers a wide range of products and services, including Diabetic Medicines, Vitamins, Minerals & Antioxidants, Ayurveda Products, Natural Hair & Skin Care.
Who are the key members and board of directors at Primus Remedies?
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Narayanam  | Director | 26-Feb-2010 | Current |
| Swapna Pasupunuri | Director | 26-Feb-2010 | Current |
| Sridevi Jonnalagadda | Director | 26-Feb-2010 | Current |
| Srinivas Gangashettywar | Director | 26-Feb-2010 | Current |
| Jonnalagadda Nagendraprasad | Director | 03-Jun-2022 | Current |
| Rakesh Pasupunuri | Director | 03-Jun-2022 | Current |
Financial Performance of Primus Remedies.
Primus Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.96% increase. The company also saw a slight improvement in profitability, with a 2.18% increase in profit. The company's net worth Soared by an impressive increase of 32.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Primus Remedies?
In 2023, Primus Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sai Primus Lifebiotech Private LimitedActive 7 years 10 monthsAjay Narayanam, Srinivas Gangashettywar and 2 more are mutual person
Charges (Loans)
₹11.19 Cr
₹0.35 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 11.19 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Nov 2021 | Axis Bank Limited | ₹4.45 M | Open |
| 18 Oct 2021 | Axis Bank Limited | ₹2.40 M | Open |
| 25 Oct 2019 | Axis Bank Limited | ₹9.75 Cr | Open |
| 29 Feb 2016 | Axis Bank Limited | ₹7.50 M | Open |
| 07 Sep 2020 | Axis Bank Limited | ₹3.53 M | Satisfied |
How Many Employees Work at Primus Remedies?
Primus Remedies has a workforce of 292 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Primus Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Primus Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.